Focal salvage brachytherapy for recurrent prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective phase II study evaluates the safety and toxicity of focal salvage brachytherapy in patients with localized recurrence of prostate cancer after prior radiotherapy. The study aims to treat patients who have experienced local recurrence while ensuring that critical organs are protected from excessive radiation exposure. Patients will undergo imaging assessments to confirm localized tumors and exclude distant metastases before receiving the brachytherapy treatment. The goal is to provide a targeted approach that may improve outcomes for patients with recurrent prostate cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histopathologically confirmed by biopsy (fusion mapping biopsy preferred) recurrence of prostate cancer after prior radical radiotherapy (brachytherapy, external beam radiotherapy alone or with brachytherapy boost, stereotaxic radiotherapy)
* Localized tumor lesion assessed by MRI or in the case of MR contraindications with TRUS and CT
* Exclusion of distant metastases using CT, MR, or PET imaging
* PSA doubling time over six months
* PSA value \<10 ng / ml
* No anti-androgen treatment in the year prior
* Dysuria on the IPSS (International Prostate Symptom Score) ≤ 20 points
* General condition according to the WHO scale ≤ 2
* Signing informed consent to participate in the study

Exclusion Criteria:

* PSA value\> 10ng / ml
* General condition according to the WHO scale\> 2
* Dysuria on the IPSS scale\> 20 points
* PSA doubling time \<6 months
* Inability to discontinue anticoagulants.
* An active urinary tract infection.
* Contraindications to general anesthesia
* Active inflammatory bowel diseases.
* Second active cancer or treatment with completion less than 3 years earlier, except for low-stage skin cancer
* Estimated Survival \<5 years

Where it's running

• Greater Poland Cancer Centre / Brachytherapy Department
  Poznan, Greater Poland Voivodeship, Poland Recruiting

Study contacts

• Principal investigator: Wojciech Burchardt, PhD, MD — Greater Poland Cancer Centre / Brachytherapy Department
• Study coordinator: Wojciech Burchardt, PhD, MD
• Email: wojciech.burchardt@wco.pl
• Phone: +48505149659

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.